Story thread · 2 reports / 2 sources
Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO
financialpost.com · 12d
Attovia Therapeutics Inc., an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5 million in a US initial public offering.
First report: Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO — bloomberg.com, 12d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.